EGFR and neoplasm: A systematic review and meta-analysis [77] involving 4527 advanced NSCLC patients indicated that compared to tumor tissue, the combined sensitivity and specificity of ctDNA EGFR mutation in plasma samples was 0.70 and 0.98, respectively.